COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Boston Scientific ENOVUS Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00246038
Recruitment Status : Withdrawn (Sponsor cancelled the development program, and never conducted the study.)
First Posted : October 30, 2005
Last Update Posted : August 31, 2015
Information provided by:
Boston Scientific Corporation

Brief Summary:
A prospective, actively controlled, consecutively enrolling, non-randomized multi center clinical evaluation of the safety and efficacy of the Boston Scientific ENOVUS AAA Endograft when used in the treatment of patients with AAA (Treatment Group) as compared to patients treated with conventional open surgery (Control Group).

Condition or disease Intervention/treatment Phase
Abdominal Aortic Aneurysm Device: Boston Scientific ENOVUS AAA Endograft Phase 2

Detailed Description:

The primary objectives of this study are to determine whether the Boston Scientific ENOVUS AAA Endograft is a safe and effective method of treating AAA's in those patients considered to be suitable candidates for open surgical repair. The safety of the Boston Scientific ENOVUS AAA Endograft will be determined by comparing the rate of major morbidity in the Treatment Group against the rate of major morbidity in the Control Group within 30 days of the initial procedure. The efficacy of the Boston Scientific ENOVUS AAA Endograft will be determined by evaluating the proportion of patients in the Treatment Group that are free from AAA rupture and conversion to open surgical repair within 1 year of the initial procedure.

The secondary safety endpoints will be compared between the Treatment and Control Groups:Mortality rates at 30 days and 1 year, AAA related mortality at 30 days and 1 year. The secondary efficacy endpoints will be evaluated in the Treatment Group only and include: Technical success, enlargement of AAA, migration, significant endoleak, and loss of device integrity. Secondary Clinical Utility endpoints will be compared between the Treatment and Control groups and will include: blood loss, duration of procedure, ICU stay, length of hospital stay, and duration of anesthesia.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Evaluation of the Safety and Efficacy of the Boston Scientific ENOVUS AAA Endograft in the Treatment of Abdominal Aortic Aneurysms

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Efficacy will evaluate patients (Treatment Group) free from AAA rupture and surgical conversion within 1 year of the initial procedure.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All patients must meet all of the following inclusion criteria to be eligible for enrollment into this study:

    1. Patient is > 18 years of age
    2. Females of childbearing potential have a negative pregnancy test at the time of treatment
    3. Patient has signed an Institutional Review Board (IRB) approved Informed Consent Form
    4. Patient is considered by the treating physician to be a candidate (i.e., categories I, II, or III) for elective open surgical repair of the AAA per American Society of Anesthesiology (ASA) refer to Appendix II. ASA grade IV patients may be enrolled provided their life expectancy is greater than 1 year.
    5. Patient has an infrarenal abdominal aortic aneurysm that meets at least one of the following:•Abdominal aortic aneurysm >4.5 cm in diameter

      • Aneurysm has increased in size by 0.5 cm in last 6 months.
      • Maximum diameter of aneurysm exceeds one and one-half times the transverse dimension of an adjacent normal aortic segment
    6. Patient must be willing to comply with all required follow-up exams (open surgical control patients are followed through one year, Treatment Group patients are followed through five years in the study with lifelong follow up by physician thereafter).

Exclusion Criteria:

  • Patients that meet ANY of the following are not eligible for enrollment into the study:

    1. Aneurysm dissection
    2. Acutely ruptured aneurysm
    3. Acute vascular injury
    4. Need for emergent surgery
    5. Patient has a known thoracic aortic aneurysm or dissection.
    6. Patient has unstable angina (defined as angina characterized by progressive increase in anginal symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina)
    7. Patient has history of connective tissue disease (e.g., Marfan's or Ehler's-Danlos syndrome).
    8. Patient has history of bleeding disorders or refuses blood transfusions.
    9. Patient has baseline serum creatinine level >2.0 mg/dl
    10. Patient has a known hypersensitivity or contraindication to anticoagulation that is not amenable to pre-treatment.
    11. Patient has a mycotic aneurysm or has an active systemic infection
    12. Patient is morbidly obese or has other clinical conditions that severely inhibit X-ray visualization of the aorta
    13. Patient has a limited life expectancy of less than 1 year
    14. Patient is currently participating in another investigational device or drug clinical trial
    15. Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving this treatment, pre-treatment, and post-treatment procedures and evaluations.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00246038

Sponsors and Collaborators
Boston Scientific Corporation
Layout table for investigator information
Principal Investigator: Rodney A. White, MD; Chief, Vascular Surgery University of California, Los Angeles
Principal Investigator: W. Anthony Lee, MD; Assistant Professor of Surgery University of Florida
Layout table for additonal information
Responsible Party: Pamela Grady, PhD, Director, Clinical Programs, Boston Scientific Corporation Identifier: NCT00246038    
Other Study ID Numbers: 810-0001
First Posted: October 30, 2005    Key Record Dates
Last Update Posted: August 31, 2015
Last Verified: August 2015
Keywords provided by Boston Scientific Corporation:
Abdominal Aortic Aneurysm
Aortic Aneurysm
Stent Graft
Vascular Prostheses
Additional relevant MeSH terms:
Layout table for MeSH terms
Aortic Aneurysm
Aortic Aneurysm, Abdominal
Vascular Diseases
Cardiovascular Diseases
Aortic Diseases